Torrent Pharma. Q3 FY26 Earnings Analysis
Published 3 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.8L Cr
Price
₹4,849.2
Market Cap
₹1.8L Cr
P/E Ratio
82.7
How does Torrent Pharma. rank in Pharmaceuticals & Biotechnology?
Compare Torrent Pharma. against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Earnings Summary
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
📊 Revenue & Sales Performance
- →India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. (Page 4)
- →Brazil branded generics market grew 10% YoY; Torrent grew 13% with healthy volume growth and mid-single digit pricing increase; expects 5-6 new product launches in Brazil. (Pages 3, 14)
- →U.S. business saw 12% growth in constant currency; targeting a directional increase in sales with at least 5-7 launches per year and aims to cross $200 million annual sales by FY27. (Pages 3, 9)
- →Germany facing supply disruptions, growth affected; alternative supplier efforts ongoing but will take 3-4 quarters. (Page 4)
- →JB Pharma acquisition synergy target INR 400-450 crores over 2-3 years, largely cost synergies initially; revenue synergies expected after integration. (Pages 6, 14)
- →Medium-term focus on growth in emerging markets like Russia, Mexico, Philippines toward $50 million markets over 3-4 years. (Page 12)
📈 Profitability & Margins
- →Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses.
- →India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases.
- →In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%.
- →U.S. business (~$36 million revenue) aims to surpass $200 million sales by FY27, driven by 5-7 launches per year.
- →Cost synergies from JB acquisition targeted at INR 400-450 crores over 2-3 years, with up to 20% realized in year one and scaling thereafter.
- →JB’s EBITDA margin expected to improve from ~28-29% closer to Torrent’s 32-33% over time post-merger.
- →Net debt expected to reduce, with net debt to EBITDA ratio reducing to ~0.6 by FY29.
- →Overall operating EBITDA margin stable around 32.9%, with margin upside from synergies post-JB integration.
🏗️ Capital Expenditure Plans
- →There is no explicit mention of current or future capex/capital investment or strategic investment in the provided pages (up to page 15).
- →However, there is mention of ongoing work to address supply disruptions in Germany by moving some products to Torrent's own facilities, which implies some capital investment in manufacturing (Page 4).
- →For GLP-1 injectable products, Torrent does not have fill and finish capacity and will partner for manufacturing and launch, indicating a strategic partnership approach rather than immediate capex (Page 4).
- →The company is preparing future large markets like Russia, Mexico, and the Philippines for growth, which may involve strategic investments but no direct capex details are provided (Page 12).
- →Overall, the focus appears to be on integration with the JB acquisition, operational synergies, and expanding market presence rather than large announced capex at this stage.
💰 Fundraising & Capital Structure
- →No explicit mention of any current or planned new fundraising through equity or debt in the call.
- →Net debt as of December is roughly INR 880 crores.
- →Post-acquisition, net EBITDA to net debt ratio is expected to improve with net debt to EBITDA around 1-1.1x in FY '28 and approximately 0.6x by FY '29.
- →Average cost of interest is about 7.6%.
- →The company is targeting to repay debt and get back to a net cash position possibly by FY '29, indicating no immediate new debt raising plans.
- →Focus appears on cost synergies and margin improvement rather than raising new funds.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Torrent Pharma. Q3 FY26 results?
India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹184,448 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
There is no explicit mention of current or future capex/capital investment or strategic investment in the provided pages (up to page 15).
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.